Related Experiment Videos
Test models and new directions in dementia research
1Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Harlow, UK.
Psychopharmacology Series
|January 1, 1988
Summary
Dementia psychopharmacology faces challenges due to a lack of effective treatments. Research explores neurotransmitter replacement, excitotoxins like quinolinic acid, and neurotrophic factors for potential neuroprotection.
Area of Science:
- Neuroscience
- Pharmacology
- Gerontology
Background:
- Psychopharmacology research for dementia is hindered by the absence of effective treatments.
- Current efforts focus on neurotransmitter and neuropeptide replacement, particularly in the cholinergic system.
- Investigating deficits in noradrenaline, serotonin, and somatostatin is also of interest.
Purpose of the Study:
- To explore novel therapeutic avenues in dementia psychopharmacology.
- To investigate the role of excitotoxins and neurotrophic factors in neurodegeneration.
- To identify potential agents for limiting or slowing neurodegenerative processes.
Main Methods:
- Examining the potential of replacing defective brain chemical transmitters and neuropeptides.
- Studying glutamate-related excitotoxins, such as quinolinic acid, as causative agents.
- Investigating glutamate receptor antagonists (e.g., MK-801) and neurotrophic factors (e.g., nerve growth factor).
Main Results:
- The cholinergic system is a primary focus for neurotransmitter replacement strategies.
- Glutamate excitotoxins like quinolinic acid are being studied as potential causes of cerebral degeneration.
- Glutamate receptor antagonists and neurotrophic factors show promise in protecting neurons.
Conclusions:
- Developing effective dementia treatments remains a significant challenge.
- Novel approaches involve targeting excitotoxicity and promoting neuroprotection.
- Further research into glutamate pathways and neurotrophic factors may yield future therapeutic strategies.